BodeVet Appoints Dr. Jennifer Kishbaugh as Clinical Research Associate
ROCKVILLE, MD. (July 12, 2018) – BodeVet, a developer of advanced transfusion treatment options for the veterinary industry, announced the recent hire of a new clinical research associate, Jennifer Kishbaugh, DVM. Her new role will include developing a lyophilized platelet product from Asian elephant platelets to be used for supportive care in elephant calves suffering from Elephant Endotheliotrophic Herpes Virus (EEHV), which is a highly fatal virus.
“We are pleased to have Dr. Kishbaugh join our team as we continue to grow our staff at BodeVet,” said Anne Hale, DVM, Chief Technical Officer at BodeVet. “Dr. Kishbaugh’s extensive research background and understanding of clinical zoological medicine will be an asset to us as we develop new platelet products focused on serving the wildlife population.”
Although the company is primarily focused on canine and equine conditions, BodeVet is also supporting work focused on endangered species, which Dr. Kishbaugh’s work will support. She will be responsible for clinical study design, data collection and reporting.
Dr. Kishbaugh’s most recent position was at the Smithsonian’s Global Health Program where she served as a Judy and John W. McCarter, Jr. Global Health Veterinary Intern. During her tenure there, she gained beneficial experience researching EEHV and platelet applications. Previous research experience also includes participating in population genetics and freshwater ecology research through the St. Kitts Sea Turtle Monitoring Network and the St. Kitts Sea Turtle Monitoring Network Shorebird Project. Her past work history also includes employment in numerous specialty and emergency veterinary hospitals. Additionally, her two years of mentorship at the Maryland Zoo in Baltimore provided her with valuable experience in clinical zoological medicine.
Dr. Kishbaugh holds a bachelor of arts degree in biology from Buffalo State College and a doctorate of veterinary medicine from Ross University School of Veterinary Medicine.
BodeVet, Inc., a wholly owned subsidiary of Cellphire, Inc., is staffed and advised by world leaders in veterinary transfusion medicine. Formed in 2015, BodeVet’s mission is to promote animal health and welfare by developing and delivering new treatment solutions to veterinary medical practitioners. The company uses technology borrowed from Cellphire, a biotechnology company established in early 2006, to develop novel blood products for use in hemostasis and regenerative medicine in veterinary medicine.
# # #
(877) 703.3824 x106